Pathologic Heterogeneity in Clinically Diagnosed Corticobasal Degeneration
Neurol 53:795-800, Boeve,B.F.,et al, 1999
Multicentre European Study of Thalamic Stimulation in Paarkinsonisn and Essential Tremor
JNNP 66:289-296, Limousin,P.,et al, 1999
Progression of Parkinsonian Signs in Parkinson Disease
Arch Neurol 56:334-337, Louis,E.D.,et al, 1999
Low-Dose Clozapine for the Treatment of Drug-Induced Psychosis in Parkinson's Disease
NEJM 340:757-763,801, The Parkinson Study Group, 1999
Neurologic Side Effects in Neuroleptic-Naive Patients Treated with Haloperidol or Risperidone
Neurol 52:782-785, Rosebush,P.I.&Mazurek,M.F., 1999
Diagnostic Criteria for Parkinson Disease
Arch Neurol 56:33-39, Gelb,D.J.,et al, 1999
Magnetic Resonance Imaging-Based Volumetry Differentiates Idiopathic Parkinson's Syndrome from Multiple System Atrophy and Progressive Supranuclear Palsy
Ann Neurol 45:65-74, Schulz,J.B.,et al, 1999
Susceptibility to Neuroleptic Malignant Syndrome in Parkinson's Disease
Neurol 52:777-781, Ueda,M.,et al, 1999
Parkinson Disease in Twins,An Etiologic Study
JAMA 281:341-346,376, Tanner,C.M.,et al, 1999
Clinical Correlates of Vascular Parkinsonism
Arch Neurol 56:98-102, Winikates,J.&Jancovic,J., 1999
Mortality Cancer Risk in Parkinsonian Patients:A Population-Based Study
Neurol 52:395-398, Vanacore,N.,et al, 1999
Long-Term Evaluation of Bilateral Fetal Nigral Transplantation in Parkinson Disease
Arch Neurol 56:179-187, Hauser,R.A.,et al, 1999
Parkinsonism after Taking Ecstasy
NEJM 340:1443, Mintzer,S.,et al, 1999
Transient Acute Depression Induced by High-Frequency Deep-Brain Stimulation
NEJM 340:1476-1480,1500, Bejjani,B-P.,et al, 1999
Clinicopath Conf:Multisystem Neurodegenerative Disease with Dementia Pugilistica
NEJM 340:1269-1277, Case 12-1999, 1999
The Effect of Estrogen Replacement on Early Parkinson's Disease
Neurol 52:1417-1421, Sanders-Pullman,R.,et al, 1999
Botulinum Toxin is a Useful Treatment in Excessive Drooling of Saliva
JNNP 67:697, Bhatia,K.P.,et al, 1999
Drug-Induced Movement Disorders
Neurol Clin 16:125-139, Diederich,N.J. & Goetz,C.G., 1998
Olfactory Dysfunction in Guamanian ALS,Parkinsonism,and Dementia
Neurol 51:1672-1677, Ahlskog,J.E.,et al, 1998
Parkinson's Disease
NEJM 339:1044-1053,1130-1143, Lang,A.E.&Lozano,A.M., 1998
Electrical Stimulation of the Subthalamic Nucleus in Advanced Parkinson's Disease
NEJM 339:1105-1111, Limousin,P.,et al, 1998
Unilateral Thalamic Deep Brain Stimulation for Refractory Essential Tremor and Parkinson's Disease Tremor
Neurol 51:1063-1069, Ondo,W.,et al, 1998
Bilateral High-Frequency Stimulation of the Internal Globus Pallidus in Advanced Parkinson's Disease
Ann Neurol 44:953-961, Volkmann,J.,et al, 1998
Progressive Supranuclear Palsy, A Survey of the Disease Course
Neurol 50:1637-1647, Santacruz,P.,et al, 1998
Pharmacological Therapy in Progressie Supranuclear Palsy
Arch Neurol 55:1099-1102, Kompoliti,K.,et al, 1998
Double-Blind Evaluation of Subthalamic Nucleus Deep Brain Stimulation in Advanced Parkinson's Disease
Neurol 51:850-855, Kumar,R.,et al, 1998
Effect of Selegiline on Mortality in Patients with Parkinson's Disease
Neurol 51:825-830, Olanow,C.W.,et al, 1998
Motor, Cognitive, and Behavioral Performance Following Unilateral Ventroposterior Pallidotomy for Parkinson Disease
Arch Neurol 55:1201-1208, Masterman,D.,et al, 1998
Early Dopaminergic Drug-Induced Hallucinations in Parkinsonian Patients
Neurol 51:811-814, Goetz,C.G.,et al, 1998
Ropinirole for the Treatment of Early Parkinson Disease
Arch Neurol 55:1211-1216, Sethi,K.D.,et al, 1998
Natural History & Survival of 14 Pts with Corticobasal Degeneration Confirmed as Postmortem Exam
JNNP 64:184-189, Wenning,G.K.,et al, 1998
Subcutaneous Apomorphine in Parkinson's Disease
Effective Yet Underused, BMJ 316:6411998., , 1998
Morality in DATATOP:A Multicenter Trial in Early Parkinson's Disease
Parkinson Study Group, Ann Neurol 43:318-3251998., , 1998
An Algorithm (Decision Tree) for the Management of Parkinson's Disease:Trtm Guidelines
Neurol 50:S1-S57, Olanow,C.W.&Koller,W.C., 1998
Visual Fields in Patients with Posterior GPi Pallidotomy
Neurol 50:258-265, Biousse,V.,et al, 1998
Stereotactic pallidotomy for Trtm of Parkinson's Disease, Efficacy & Adverse Effects at 6 Mo in 26 Pts
Neurol 50:434-438, Shannon,K.M.,et al, 1998
Assessment of Motor Function After Stereotactic Pallidotomy
Neurol 50:266-270, Ondo,W.G.,et al, 1998
Hereditary Form of Parkinsonism-Dementia
Ann Neurol 43:768-781, Muenter,M.D.,et al, 1998
The Risk of Parkinson's Disease with Exposure to Pesticides, Farming, Well Water, and Rural Living
Neurol 50:1346-1350, Gorell,J.M.,et al, 1998
Mortality in People Taking Selegiline:Observational Study
BMJ 317:252-254, Thorogood,M.,et al, 1998
Managing the Neuropsychiatric Symptoms of Parkinson's Disease
Neurol 50:S33-S38, Lieberman,A., 1998
Investig of PDRG of UK into Excess Mortality Seen/Comb Levodopa & Selegiline Trmt in Pts with Early, Mild Parkinson's Dis
BMJ 316:1191-1196, Ben-Shlomo,Y.,et al, 1998
Functional Neurosurgery for parkinson's Disease, Has Come a Long Way, Though Much Remains Experimental
BMJ 316:1259-1260, Quinn,N.&Bhatia,K., 1998
Pallidotomy for Parkinson's Disease:Hitting the Target
Lancet 351:998-999, Golbe,L.I., 1998
Neuropsychological Consequences of Posteroventral Pallidotomy for the Treatment of Parkinson's Disease
Neurol 51:207-215, Trepanier,L.L.,et al, 1998
Cognitive Functioning After Pallidotomy for Refractory Parkinson's Disease
JNNP 65:150-154, 1481998., Perrine,K.,et al, 1998
Olanzapine Can Worsen Parkinsonism
Neurol 50:1183-1184, Jimenez-Jimenez,F.J.,et al, 1998
Olanzapine in the Treatment of Dopaminomimetic Psychosis in Patients with Parkinson's Disease
Neurol 50:1195-1196, Wolters,E.C.,et al, 1998
Tolcapone for Parkinson's Disease
The Medical Letter 40:60-61, , 1998
Random, Placebo-Contr Study of Tolcapone in Pts with Fluctuating Parkinson Dis Trtd With Levodopa-Carbidopa
Arch Neurol 55:1089-1095, Adler,C.H.,et al, 1998